In total, around 320 analyst studies were published on Hannover Re and the insurance sector in the 2017 financial year. By the end of the year 32 analysts had handed down opinions on Hannover Re: nine analysts (ten) recommended the Hannover Re share as “buy” or “overweight”. Altogether 18 opinions (17) were a “hold”, making this the most common. “Underweight” or “sell” recommendations were issued a total of five (seven) times. The analysts’ average price target continued to move higher in the year under review, increasing from EUR 101.34 at the start of the financial year to EUR 110.49 at year-end. This development is particularly pleasing in view of what is still a relatively superior valuation measured against peer companies.